Insight Molecular Diagnostics Inc. Common Stock (IMDX)

FairStock Score: 26/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Precision diagnostics can be a good business if a test becomes standard of care, but I look for evidence of durable demand and owner earnings. Insight Molecular Diagnostics has neither yet. In fiscal 2025, the year ended 2025-12-31, revenue was $4.1 million and net loss was $50.2 million; in fiscal 2024, the year ended 2024-12-31, revenue was $1.9 million and net loss was $60.7 million. The latest quarter was worse: fiscal Q2 2026, the quarter ended 2026-06-30, had revenue of $239,000, net loss of $11.3 million, and diluted EPS of -$0.31. Fiscal Q1 2026, the quarter ended 2026-03-31, revenue was only $32,000. FairStock calculations at the 2026-10-13 close show P/E -1.97 and FCF yield -31.7%; other FairStock calculations show ROCE -57.82%, Piotroski 3/9, and Altman Z -19.23. TTM free cash flow was -$31.0 million. The Lynch category is none, because the company lost money in each of the last four years. The market value of $97.8 million dwarfs the $4.1 million of fiscal 2025 revenue, so the price is a hope-based option on DetermaCNI and DetermaIO. Those products may matter clinically, and annual revenue rose from $1.5 million in fiscal 2023, the year ended 2023-12-31, to $4.1 million in fiscal 2025, the year ended 2025-12-31, but the recent quarterly decline and heavy cash burn are red flags. Without a margin of safety in earnings, assets, or cash flow, I would call this speculative rather than investment-grade. Graham would demand proof; Buffett would wait for a moat and consistent profits.

In plain English: Insight Molecular Diagnostics makes precision cancer tests and is developing tests to monitor treatment and predict immunotherapy response. The business is very early: sales are tiny, it has lost money for years, and it burns cash. At the 2026-10-13 close of $2.99, the price looks expensive and speculative compared with current sales and losses.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer